Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This is a study to assess the effects of darapladib on the cardiac conduction of the heart as compared to placebo and moxifloxacin. This a four period crossover design with each period lasting about 10 days. There will be a 7 to 10 day wash out in between each period.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Body weight greater than 50 kg (110 lbs) and a body mass index between 19 and 30
Signed and dated written informed consent prior to admission to the study
Subject is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions
history of asthma or severe allergic reactions
history of alcohol or drug abuse
use of prescription or non-prescription drugs or vitamins or herbal supplements
history of cholecystectomy or biliary tract disease